Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials
- PMID: 33298370
- PMCID: PMC7698829
- DOI: 10.1053/j.jvca.2020.11.057
Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials
Abstract
Objectives: Efficacy and safety of corticosteroids in patients with 2019-nCoV (novel coronavirus 2019) infection still are debated. Because large randomized clinical trials (RCTs) and a well-conducted meta-analysis on the use of corticosteroids, focused on patients with coronavirus disease (COVID-19) in intensive care units, recently were published, a meta-analysis of RCTs on corticosteroids therapy in patients with different disease severity was performed to evaluate the effect on survival.
Design: A meta-analyses of RCTs was performed.
Setting: Patients admitted to hospital.
Participants: Patients with coronavirus disease.
Interventions: Administration of corticosteroids.
Measurements and main results: A search was performed for RCTs of adult patients with acute hypoxemic failure related to 2019-nCoV infection who received corticosteroids versus any comparator. The primary endpoint was mortality rate. Five RCTs involving 7,692 patients were included. Overall mortality of patients treated with corticosteroids was slightly but significantly lower than mortality of controls (26% v 28%, relative risk {RR} = 0.89 [95% confidence interval {CI} 0.82-0.96], p = 0.003). The same beneficial effect was found in the subgroup of patients requiring mechanical ventilation (RR = 0.85 [95% CI 0.72-1.00], p = 0.05 number needed to treat {NNT} = 19). Remarkably, corticosteroids increased mortality in the subgroup of patients not requiring oxygen (17% v 13%, RR = 1.23 [95% CI 1.00-1.62], p = 0.05 number needed to harm {NNH} = 29). Tests for comparison between mechanically ventilated subgroups and those not requiring oxygen confirmed that treatment with corticosteroids had a statistically significant different effect on survival. Patients treated with corticosteroids had a significantly lower risk of need for mechanical ventilation.
Conclusions: Corticosteroids may be considered in severe critically ill patients with COVID-19 but must be discouraged in patients not requiring oxygen therapy. Urgently, further trials are warranted before implementing this treatment worldwide.
Keywords: 2019-nCoV; COVID-19; corticosteroids; mechanical ventilation; meta-analyses; mortality.
Copyright © 2020 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5. Trials. 2021. PMID: 33430924 Free PMC article.
-
Inhaled corticosteroids on mortality in COVID-19: A systematic review and meta-analysis of randomized controlled trials.J Investig Med. 2024 Aug;72(6):567-573. doi: 10.1177/10815589241249997. Epub 2024 May 15. J Investig Med. 2024. PMID: 38747526
-
Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes.Crit Care. 2020 Dec 14;24(1):696. doi: 10.1186/s13054-020-03400-9. Crit Care. 2020. PMID: 33317589 Free PMC article.
-
Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data.Clin Microbiol Infect. 2021 Apr;27(4):603-610. doi: 10.1016/j.cmi.2020.11.035. Epub 2020 Dec 8. Clin Microbiol Infect. 2021. PMID: 33301928 Free PMC article.
-
Effects of different corticosteroid therapy on severe COVID-19 patients: a meta-analysis of randomized controlled trials.Expert Rev Respir Med. 2022 Jan;16(1):79-89. doi: 10.1080/17476348.2021.1983429. Epub 2021 Sep 30. Expert Rev Respir Med. 2022. PMID: 34541972 Free PMC article.
Cited by
-
Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense.Bosn J Basic Med Sci. 2021 Oct 1;21(5):515-527. doi: 10.17305/bjbms.2020.5543. Bosn J Basic Med Sci. 2021. PMID: 33714258 Free PMC article. Review.
-
Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt?Molecules. 2022 Dec 15;27(24):8919. doi: 10.3390/molecules27248919. Molecules. 2022. PMID: 36558048 Free PMC article. Review.
-
Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19.Am J Physiol Lung Cell Mol Physiol. 2022 Sep 1;323(3):L372-L389. doi: 10.1152/ajplung.00136.2022. Epub 2022 Jun 28. Am J Physiol Lung Cell Mol Physiol. 2022. PMID: 35762590 Free PMC article.
-
Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study.Ann Intensive Care. 2021 Nov 26;11(1):159. doi: 10.1186/s13613-021-00951-0. Ann Intensive Care. 2021. PMID: 34825976 Free PMC article.
-
A hitchhiker's guide through the COVID-19 galaxy.Clin Immunol. 2021 Nov;232:108849. doi: 10.1016/j.clim.2021.108849. Epub 2021 Sep 24. Clin Immunol. 2021. PMID: 34563684 Free PMC article. Review.
References
-
- Nardelli P, Landoni G. COVID-19-related thromboinflammatory status: Microclots and beyond (editorial) Obshchaya Reanimatologiya. 2020;16:14–15.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical